Ahmed Arif, MD
Internal Medicine · Flint, MINPI 1841249836
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Novo Nordisk AS at 51.0% of the total. Reporting peaked in 2019 at $15,854 and has fallen 97.9% since, to $338 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $131.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$10K
- Novartis$5K
- Pfizer$1K
- Bayer$1K
- AstraZeneca$330
- AbbVie$254
- plus $1K from 22 others
Across 1,451 payments — averaging $2808.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$706K
- AstraZeneca$693K
- Novo Nordisk AS$473K
- Genentech, Inc.$299K
- Amgen$213K
- Bayer$209K
- plus $1.5M from 23 others
What the payments were for
- Consulting fees$5,00725%
- Travel & lodging$11,47658%
- Food & beverage$3,44817%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 8 | $10,157 |
| Novartis | 27 | $5,416 |
| Pfizer | 18 | $1,389 |
| Bayer | 4 | $1,222 |
| AstraZeneca(2 entities) | 15 | $330 |
| AbbVie(2 entities) | 16 | $254 |
| Merck | 13 | $218 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $135 |
| Nestle Healthcare Nutrition Inc. | 5 | $94 |
| Hologic Sales And Service, LLC | 3 | $73 |
| Amgen | 4 | $68 |
| Sunovion Pharmaceuticals Inc. | 5 | $67 |
| Vertex | 1 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Neurelis, Inc. | 2 | $36 |
| Nevro Corp. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Cook Medical LLC | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $13 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$8,677
- Non-Covered$1,159
How this compares
$19,930 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 114 | $152,664 |
| JardianceEmpagliflozin | 118 | $116,684 |
| EliquisApixaban | 112 | $116,232 |
| JanuviaSitagliptin Phosphate | 65 | $75,556 |
| XareltoRivaroxaban | 44 | $55,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $34,713 |
| OzempicSemaglutide | 20 | $31,621 |
| EntrestoSacubitril/Valsartan | 32 | $29,995 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 50 | $17,388 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $15,679 |
| FarxigaDapagliflozin Propanediol | 17 | $14,594 |
| MounjaroTirzepatide | 13 | $13,572 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $11,714 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 282 | $9,735 |
| PremarinEstrogens, Conjugated | 23 | $6,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $17 | $166,236127 claims |
| PfizerEliquis, Premarin | $1,389 | $122,937135 claims |
| MerckJanuvia | $218 | $75,55665 claims |
| Johnson & JohnsonXarelto | $14 | $55,24744 claims |
| AstraZenecaSymbicort, Farxiga | $330 | $30,27375 claims |
| NovartisEntresto | $5,416 | $29,99532 claims |
| Sanofi-aventis U.S. LLCLantus | $48 | $2,08319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Flint
- Sajjad GulFlint$39K
- Henry MendozaFlint$29K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.